Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Taku Fujimura

Showing results (221-230 of 283) with videos related to

Pageof 29
Sort By:
The Journal of Dermatology|March 25, 2025
Two cases of advanced melanoma with BRAF L597 mutation: Options for systemic treatmentRyo Amagai, Taku Fujimura, Yumi Kambayashi, et al.
The Journal of Dermatology|April 17, 2024
Radiation-induced cutaneous squamous cell carcinoma showing a significant response to pembrolizumab: A case reportManami Takahashi-Watanabe, Taku Fujimura, Ryo Amagai, et al.
European Journal of Dermatology : EJD|August 28, 2024
Steroid-resistant Vogt-Koyanagi-Harada-like uveitis due to BRAF/MEK inhibitor, successfully treated with adalimumabManami Takahashi-Watanabe, Taku Fujimura, Ryo Amagai, et al.
Brain Research|March 15, 2016
Temporal profile of magnetic resonance angiography and decreased ratio of regulatory T cells after immunological adjuvant administration to mice lacking RNF213, a susceptibility gene for moyamoya diseaseAtsushi Kanoke, Miki Fujimura, Kuniyasu Niizuma, et al.
Case Reports in Dermatology|February 7, 2012
Successful Treatment of MMP-9-Expressing Angiosarcoma with Low-Dose Docetaxel and BisphosphonateMasaya Ishibashi, Taku Fujimura, Akira Hashimoto, et al.
Frontiers in Immunology|May 23, 2024
Plasminogen activator inhibitor-1 promotes immune evasion in tumors by facilitating the expression of programmed cell death-ligand 1Abd Aziz Ibrahim, Taku Fujimura, Tomoko Uno, et al.
Skin Health and Disease|June 5, 2023
CD25 expression could be a prognostic marker of bexarotene monotherapy for cutaneous T-cell lymphomasJun Yamamoto, Kentaro Ohuchi, Ryo Amagai, et al.
Scientific Reports|October 31, 2018
Killer immunoglobulin-like receptor genotype did not correlate with response to anti-PD-1 antibody treatment in a Japanese cohortYoshihiro Ishida, Chisa Nakashima, Hiroto Kojima, et al.
Journal of Clinical Medicine|September 28, 2024
The Evaluation of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in Different Therapy Lines for Metastatic Melanoma: A Retrospective StudySaki Okuda-Hiwatashi, Ryo Amagai, Taku Fujimura, et al.
The Journal of Dermatology|March 25, 2020
Case series of cutaneous T-cell lymphomas treated with bexarotene-based therapyTaku Fujimura, Yota Sato, Kayo Tanita, et al.
Pageof 29

Showing results (221-230 of 283) with videos related to

Sort By:
Pageof 29
The Journal of Dermatology|March 25, 2025
Two cases of advanced melanoma with BRAF L597 mutation: Options for systemic treatmentRyo Amagai, Taku Fujimura, Yumi Kambayashi, et al.
The Journal of Dermatology|April 17, 2024
Radiation-induced cutaneous squamous cell carcinoma showing a significant response to pembrolizumab: A case reportManami Takahashi-Watanabe, Taku Fujimura, Ryo Amagai, et al.
European Journal of Dermatology : EJD|August 28, 2024
Steroid-resistant Vogt-Koyanagi-Harada-like uveitis due to BRAF/MEK inhibitor, successfully treated with adalimumabManami Takahashi-Watanabe, Taku Fujimura, Ryo Amagai, et al.
Brain Research|March 15, 2016
Temporal profile of magnetic resonance angiography and decreased ratio of regulatory T cells after immunological adjuvant administration to mice lacking RNF213, a susceptibility gene for moyamoya diseaseAtsushi Kanoke, Miki Fujimura, Kuniyasu Niizuma, et al.
Case Reports in Dermatology|February 7, 2012
Successful Treatment of MMP-9-Expressing Angiosarcoma with Low-Dose Docetaxel and BisphosphonateMasaya Ishibashi, Taku Fujimura, Akira Hashimoto, et al.
Frontiers in Immunology|May 23, 2024
Plasminogen activator inhibitor-1 promotes immune evasion in tumors by facilitating the expression of programmed cell death-ligand 1Abd Aziz Ibrahim, Taku Fujimura, Tomoko Uno, et al.
Skin Health and Disease|June 5, 2023
CD25 expression could be a prognostic marker of bexarotene monotherapy for cutaneous T-cell lymphomasJun Yamamoto, Kentaro Ohuchi, Ryo Amagai, et al.
Scientific Reports|October 31, 2018
Killer immunoglobulin-like receptor genotype did not correlate with response to anti-PD-1 antibody treatment in a Japanese cohortYoshihiro Ishida, Chisa Nakashima, Hiroto Kojima, et al.
Journal of Clinical Medicine|September 28, 2024
The Evaluation of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in Different Therapy Lines for Metastatic Melanoma: A Retrospective StudySaki Okuda-Hiwatashi, Ryo Amagai, Taku Fujimura, et al.
The Journal of Dermatology|March 25, 2020
Case series of cutaneous T-cell lymphomas treated with bexarotene-based therapyTaku Fujimura, Yota Sato, Kayo Tanita, et al.
Pageof 29